VRAX vs VRCA

Virax Biolabs Group Limited vs Verrica Pharmaceuticals Inc. — Valuation Comparison 2026

VRAX

Biotechnology
Virax Biolabs Group Limited
Quality
1.6
out of 10
Value Trap
6
SAFE
Price
$0.21
Last close
Models
8/13
Active
VS

VRCA

Biotechnology
Verrica Pharmaceuticals Inc.
Quality
5.4
out of 10
Value Trap
30
LOW
Price
$6.04
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType VRAX Fair ValueVRAX Upside VRCA Fair ValueVRCA Upside
Bayesian DCF Intrinsic $0.06 -73.5% $1.50 -75.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.41 +85.4% $2.61 -56.8%
PWERM Option-Based $0.28 +125.8% $5.64 -6.6%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for VRAX vs VRCA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VRAX vs VRCA — Which Stock Is More Undervalued?

VRCA scores higher with a 5.4/10 quality rating vs VRAX's 1.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Virax Biolabs Group Limited (VRAX) and Verrica Pharmaceuticals Inc. (VRCA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VRAX currently trades at $0.21 with a QOC of 1.6/10, while VRCA trades at $6.04 with a QOC of 5.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).